Since targeting ZIP7-mediated Zn release in breast cancer cells led to loss of cell proliferation control and invasion [52], CK2 regulated phosphorylation of ZIP7 suggests the possibility of targeting CK2 for treatment of breast cancer [190]. Here, SLC39A7 is linked to breast cancer.